{"disease":{"id":"early-alzheimers-disease","name":"early alzheimers disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04498650","title":"A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Vivoryon Therapeutics N.V.","has_results":false},{"nct_id":"NCT06996730","title":"A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Banner Health","has_results":false},{"nct_id":"NCT07496021","title":"Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"CKD Bio Corporation","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}